{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"6.7","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 1000mg/m\\^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 1.4mg/m\\^2 eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nEribulin Mesylate: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"OG000","title":"Treatment (Eribulin Mesylate and Gemcitabine Hydrochloride)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the start until progression, death, or the start of another treatment, assessed up to 12 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}